22 results on '"*PROPERDIN factor B"'
Search Results
2. Looking back on the alternative complement pathway.
- Author
-
Lachmann, Peter J.
- Subjects
- *
PROPERDIN factor B , *COMPLEMENT activation , *IMMUNOGLOBULINS , *BLOOD serum analysis , *CHEMICAL reactions - Abstract
The alternative pathway of complement originated from the Properdin pathway originally described by the Pillemer laboratory in the 1950s. This work generated great controversy and it took several decades for a consensus on its components, its reaction sequence and its functions to emerge. This paper reviews this history and attempts to clarify some of the ambiguities that remain. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Polymorphisms in genes related to the complement system and antibody-mediated cardiac allograft rejection.
- Author
-
Marrón-Liñares, Grecia M., Núñez, Lucía, Crespo-Leiro, María G., Barge-Caballero, Eduardo, Pombo, Jorge, Paniagua-Martin, María Jesús, Suarez-Fuentetaja, Natalia, Cid, Javier, Grille-Cancela, Zulaika, Muñiz-Garcia, Javier, Tan, Carmela D., Rodríguez, E. Rene, Vázquez-Rodríguez, José Manuel, and Hermida-Prieto, Manuel
- Subjects
- *
HEART transplantation , *GENETIC polymorphisms , *HOMOGRAFTS , *IMMUNOGLOBULINS , *PROPERDIN factor B - Abstract
Background Heart transplantation (HT) is a life-saving treatment for patients with end-stage heart failure. One of the main problems after HT is the humoral response termed antibody-mediated rejection (AMR). Complement activation plays a key role in AMR contributing to graft damage. The aim of this study was to analyze genetic variants in genes related to the complement pathways that could be associated with the development of AMR. Methods Analysis of 51 genes related to the complement pathway was performed by next-generation sequencing in 46 HT recipients, 23 with and 23 without AMR. Statistical analysis was performed with SNPstats and R. Results We identified 2 single nucleotide polymorphisms, 1 in the mannose-binding lectin 2 gene (p.Gly54Asp- MBL2 ) and 1 in the complement factor properdin gene (p.Asn428(p=)- CFP ), that showed significant association with the absence and development of AMR, respectively. Moreover, the presence of the rare allele in p.Gly54Asp- MBL2 control patients correlated with an immunodeficiency of mannose-binding lectin (6.24 ng/ml vs 207.50 ng/ml, p < 0.01), whereas the presence of the rare allele p.Asn428(p=)- CFP in patients with AMR correlated with higher levels of properdin protein (14.65 μg/ml vs 10.77 μg/ml, p < 0.05). Conclusions AMR is a complex phenotype affected by many recipient factors. Variants in p.Gly54Asp- MBL2 and p.Asn428(p=)- CFP genes, encoding mannose-binding lectin 2 and properdin, may influence the risk of AMR. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. The properdin pathway: an “alternative activation pathway” or a “critical amplification loop” for C3 and C5 activation?
- Author
-
Harrison, Richard A.
- Subjects
- *
PROPERDIN factor B , *COMPLEMENT activation , *ENZYME activation , *IMMUNITY , *WAVE amplification - Abstract
This review is not intended to cover in detail all aspects of the discovery and evolution of our understanding of the “alternative pathway” of complement activation, there are many excellent reviews that do this (see Fearon (CRC Crit Rev Immunol 1:1–32,
1979 ), Pangburn and Müller-Eberhard (Springer Semin Immunopathol 7:163–192,1984 )), but instead to give sufficient background for current concepts to be put in context. The prevailing textbook view, of components having a primary role as an alternative “pathway” for C3 activation, is challenged, with an argument developed for the primary role of the system being that of providing a surface-dependent amplification loop for both C3 and C5 activation. Whatever the mechanism by which the initial C3b molecule is generated, deposition onto a surface has the potential to target that surface for elimination. Elimination or escape from initial targeting is determined by a sophisticated and highly regulated amplification loop for C3 activation. This viewpoint of the system is then briefly developed to provide a context for therapeutic treatment of disease caused, at least in part, by dysregulated amplification of C3 activation, and to highlight some of the challenges that such therapies will face and need to address. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
5. Complement’s hidden arsenal: New insights and novel functions inside the cell.
- Author
-
Liszewski, M. Kathryn, Elvington, Michelle, Kulkarni, Hrishikesh S., and Atkinson, John P.
- Subjects
- *
COMPLEMENT (Immunology) , *NATURAL immunity , *HOSTS (Biology) , *CELL metabolism , *PROPERDIN factor B , *T cells - Abstract
A key component of both innate and adaptive immunity, new understandings of the complement system are expanding its roles beyond that traditionally appreciated. Evidence is accumulating that complement has an intracellular arsenal of components that provide not only immune defense, but also assist in key interactions for host cell functions. Although early work has primarily centered on T cells, the intracellular complement system likely functions in many if not most cells of the body. Some of these functions may trace their origins to the primitive complement system that began as a primeval form of C3 likely tasked for protection from intracellular pathogen invasion. This later expanded to include extracellular defense as C3 became a secreted protein to patrol the vasculature. Other components were added to the growing system including regulators to protect host cells from the indiscriminate effects of this potent system. Contemporary cells may retain some of these vestigial remnants. We now know that a) C3 serves as a damage-associated molecular pattern (in particular by coating pathogens that translocate into cells), b) most cells store C3 and recycle C3(H 2 O) for immediate use, and c) C3 assists in cellular survival and metabolic reprogramming. Other components also are part of this hidden arsenal including C5, properdin, factors H and B, and complement receptors. Importantly, better definition of the intracellular complement system may translate into new target discovery to assist in creating the next generation of complement therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Properdin binding to complement activating surfaces depends on initial C3b deposition.
- Author
-
Harboe, Morten, Johnson, Christina, Nymo, Stig, Ekholt, Karin, Schjalm, Camilla, Lindstad, Julie K., Pharo, Anne, Hellerud, Bernt Christian, Ekdahl, Kristina Nilsson, Mollnes, Tom Eirik, and Nilsson, Per H.
- Subjects
- *
PROPERDIN factor B , *PATTERN recognition systems , *ESCHERICHIA coli , *MYELOPEROXIDASE , *FLOW cytometry - Abstract
Two functions have been assigned to properdin; stabilization of the alternative convertase, C3bBb, is well accepted, whereas the role of properdin as pattern recognition molecule is controversial. The presence of nonphysiological aggregates in purified properdin preparations and experimental models that do not allow discrimination between the initial binding of properdin and binding secondary to C3b deposition is a critical factor contributing to this controversy. In previous work, by inhibiting C3, we showed that properdin binding to zymosan and Escherichia coli is not a primary event, but rather is solely dependent on initial C3 deposition. In the present study, we found that properdin in human serum bound dose-dependently to solid-phase myeloperoxidase. This binding was dependent on C3 activation, as demonstrated by the lack of binding in human serum with the C3-inhibitor compstatin Cp40, in C3-depleted human serum, or when purified properdin is applied in buffer. Similarly, binding of properdin to the surface of human umbilical vein endothelial cells or Neisseria meningitidis after incubation with human serum was completely C3-dependent, as detected by flow cytometry. Properdin, which lacks the structural homology shared by other complement pattern recognition molecules and has its major function in stabilizing the C3bBb convertase, was found to bind both exogenous and endogenousmolecular patterns in a completely C3-dependent manner. We therefore challenge the view of properdin as a pattern recognition molecule, and argue that the experimental conditions used to test this hypothesis should be carefully considered, with emphasis on controlling initial C3 activation under physiological conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Monomeric C-reactive protein inhibits renal cell-directed complement activation mediated by properdin.
- Author
-
O'Flynn, Joseph, van der Pol, Pieter, Dixon, Karen O., Prohászka, Zoltán, Daha, Mohamed R., and van Kooten, Cees
- Subjects
- *
C-reactive protein , *PROPERDIN factor B , *DIAGNOSTIC use of flow cytometry - Abstract
Previous studies have shown that complement activation on renal tubular cells is involved in the induction of interstitial fibrosis and cellular injury. Evidence suggests that the tubular cell damage is initiated by the alternative pathway (AP) of complement with properdin having an instrumental role. Properdin is a positive regulator of the AP, which can bind necrotic cells as well as viable proximal tubular epithelial cells (PTECs), inducing complement activation. Various studies have indicated that in the circulation there is an unidentified inhibitor of properdin. We investigated the ability of C-reactive protein (CRP), both in its monomeric (mCRP) and pentameric (pCRP) form, to inhibit AP activation and injury in vitro on renal tubular cells by fluorescent microscopy, ELISA, and flow cytometry. We demonstrated that preincubation of properdin with normal human serum inhibits properdin binding to viable PTECs. We identified mCRP as a factor able to bind to properdin in solution, thereby inhibiting its binding to PTECs. In contrast, pCRP exhibited no such binding and inhibitory effect. Furthermore, mCRP was able to inhibit properdindirected C3 and C5b-9 deposition on viable PTECs. The inhibitory ability of mCRP was not unique for viable cells but also demonstrated for binding to necrotic Jurkat cells, a target for properdin binding and complement activation. In summary, mCRP is an inhibitor of properdin in both binding to necrotic cells and viable renal cells, regulating complement activation on the cell surface. We propose that mCRP limits amplification of tissue injury by controlling properdin-directed complement activation by damaged tissue and cells. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
- Author
-
Corvillo, F., Bravo García‐Morato, M., Nozal, P., Garrido, S., Tortajada, A., Rodríguez de Córdoba, S., and López‐Trascasa, M.
- Subjects
- *
PROPERDIN factor B , *BIOMARKERS , *GLOMERULONEPHRITIS , *PROPROTEIN convertases , *SERUM , *NEISSERIA infections , *AUTOANTIBODIES - Abstract
Properdin (P) stabilizes the alternative pathway (AP) convertases, being the only known positive regulator of the complement system. In addition, P is a pattern recognition molecule able to initiate directly the AP on non-self surfaces. Although P deficiencies have long been known to be associated with Neisseria infections and P is often found deposited at sites of AP activation and tissue injury, the potential role of P in the pathogenesis of complement dysregulation-associated disorders has not been studied extensively. Serum P levels were measured in 49 patients with histological and clinical evidence of C3 glomerulopathy (C3G). Patients were divided into two groups according to the presence or absence of C3 nephritic factor (C3NeF), an autoantibody that stabilizes the AP C3 convertase. The presence of this autoantibody results in a significant reduction in circulating C3 ( P < 0·001) and C5 levels ( P < 0·05), but does not alter factor B, P and sC5b-9 levels. Interestingly, in our cohort, serum P levels were low in 17 of the 32 C3NeF-negative patients. This group exhibited significant reduction of C3 ( P < 0·001) and C5 ( P < 0·001) and increase of sC5b-9 ( P < 0·001) plasma levels compared to the control group. Also, P consumption was correlated significantly with C3 ( r = 0·798, P = 0·0001), C5 ( r = 0·806, P < 0·0001), sC5b-9 ( r = −0·683, P = 0·043) and a higher degree of proteinuria ( r = −0·862, P = 0·013). These results illustrate further the heterogeneity among C3G patients and suggest that P serum levels could be a reliable clinical biomarker to identify patients with underlying surface AP C5 convertase dysregulation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Properdin Provides Protection from Citrobacter rodentium- Induced Intestinal Inflammation in a C5a/IL-6-Dependent Manner.
- Author
-
Jain, Umang, Qi Cao, Thomas, Nikhil A., Woodruff, Trent M., Sehwaeble, Wilhelm J., Stover, Cordula M., and Stadnyk, Andrew W.
- Subjects
- *
CITROBACTER , *PROPERDIN factor B , *INTESTINAL diseases , *COMPLEMENT (Immunology) , *EPITHELIAL cells , *GENETICS - Abstract
Citrobacter rodentium is an attaching and effacing mouse pathogen that models enteropathogenic and enterohemorrhagic Escherichia coli in humans. The complement system is an important innate defense mechanism; however, only scant information is available about the role of complement proteins during enteric infections. In this study, we examined the impact of the lack of properdin, a positive regulator of complement, in C. rodentium-induced colitis. Following infection, properdin knockout (PKO) mice had increased diarrhea and exacerbated inflammation combined with defective epithelial cell-derived IL-6 and greater numbers of colonizing bacteria. The defect in the mucosal response was reversed by administering exogenous properdin to PKO mice. Then, using in vitro and in vivo approaches, we show that the mechanism behind the exacerbated inflammation of PKO mice is due to a failure to increase local C5a levels. We show that C5a directly stimulates IL-6 production from colonic epithelial cells and that inhibiting C5a in infected wild-type mice resulted in defective epithelial IL-6 production and exacerbated inflammation. These outcomes position properdin early in the response to an infectious challenge in the colon, leading to complement activation and C5a, which in turn provides protection through IL-6 expression by the epithelium. Our results unveil a previously unappreciated mechanism of intestinal homeostasis involving complement, C5a, and IL-6 during bacteria-triggered epithelial injury. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Differential Complement Activation Pathways Promote C3b Deposition on Native and Acetylated LDL thereby Inducing Lipoprotein Binding to the Complement Receptor 1.
- Author
-
Klop, Boudewijn, van der Pol, Pieter, van Bruggen, Robin, Yanan Wang, de Vries, Marijke A., van Santen, Selvetta, O'Flynn, Joseph, van de Geij, Gert-Jan M., Njo, Tjin L., Janssen, Hans W., de Man, Peter, Jukema, J. Wouter, Rabelink, Ton J., Rensen, Patrick C. N., van Kooten, Cees, and Castro Cabezas, Manuel
- Subjects
- *
LIPOPROTEINS , *LOW density lipoproteins , *LECTINS , *PROPERDIN factor B , *CARRIER proteins - Abstract
Lipoproteins can induce complement activation resulting in opsonization and binding of these complexes to complement receptors. We investigated the binding of opsonized native LDL and acetylated LDL (acLDL) to the complement receptor 1 (CR1). Binding of complement factors C3b, IgM, C1q, mannose-binding lectin (MBL), and properdin to LDL and acLDL were investigated by ELISA. Subsequent binding of opsonized LDL and acLDL to CR1 on CR1-transfected Chinese Hamster Ovarian cells (CHO-CR1) was tested by flow cytometry. Both native LDL and acLDL induced complement activation with subsequent C3b opsonization upon incubation with normal human serum. Opsonized LDL and acLDL bound to CR1. Binding to CHO-CR1 was reduced by EDTA, whereas MgEGTA only reduced the binding of opsonized LDL, but not of acLDL suggesting involvement of the alternative pathway in the binding of acLDL to CR1. In vitro incubations showed that LDL bound C1q, whereas acLDL bound to C1q, IgM, and properdin. MBL did neither bind to LDL nor to acLDL. The relevance of these findings was demonstrated by the fact that ex vivo up-regulation of CR1 on leukocytes was accompanied by a concomitant increased binding of apolipoprotein B-containing lipoproteins to leukocytes without changes in LDL-receptor expression. In conclusion, CR1 is able to bind opsonized native LDL and acLDL. Binding of LDL to CR1 is mediated via the classical pathway, whereas binding of acLDL is mediated via both the classical and alternative pathways. Binding of lipoproteins to CR1 may be of clinical relevance due to the ubiquitous cellular distribution of CR1. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection.
- Author
-
Youssif Mohammed Ali, Hayat, Azam, Saeed, Bayad Mawlood, Haleem, Kashif S., Alshamrani, Saleh, Kenawy, Hany I., Ferreira, Viviana P., Saggu, Gurpanna, Buchberger, Anna, Lachmann, Peter J., Sim, Robert B., Goundis, Dimitrios, Andrew, Peter W., Lynch, Nicholas J., and Schwaeble, Wilhelm J.
- Subjects
- *
PROPERDIN factor B , *STREPTOCOCCUS pneumoniae , *NEISSERIA meningitidis , *INFECTION , *IMMUNOTHERAPY - Abstract
Modern medicine has established three central antimicrobial therapeutic concepts: vaccination, antibiotics, and, recently, the use of active immunotherapy to enhance the immune response toward specific pathogens. The efficacy of vaccination and antibiotics is limited by the emergence of new pathogen strains and the increased incidence of antibiotic resistance. To date, immunotherapy development has focused mainly on cytokines. Here we report the successful therapeutic application of a complement component, a recombinant form of properdin (Pn), with significantly higher activity than native properdin, which promotes complement activation via the alternative pathway, affording protection against N. menigitidis and S. pneumoniae. In a mouse model of infection, we challenged C57BL/6 WT mice with N. menigitidis B-MC58 6 h after i.p. administration of Pn (100 ug/mouse) or buffer alone. Twelve hours later, all control mice showed clear symptoms of infectious disease while the Pn treated group looked healthy. After 16 hours, all control mice developed sepsis and had to be culled, while only 10% of Pn treated mice presented with sepsis and recoverable levels of live Meningococci. In a parallel experiment, mice were challenged intranasally with a lethal dose of S. pneumoniae D39. Mice that received a single i.p. dose of Pn at the time of infection showed no signs of bacteremia at 12 h postinfection and had prolonged survival times compared with the saline-treated control group (P < 0.0001). Our findings show a significant therapeutic benefit of Pn administration and suggest that its antimicrobial activity could open new avenues for fighting infections caused by multidrug-resistant neisserial or streptococcal strains. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Expression and functional analysis of properdin in zebrafish Danio rerio.
- Author
-
Zhang, Yanjie, Chen, Jiayan, Yao, Feng, Ji, Dongrui, Li, Hongyan, and Zhang, Shicui
- Subjects
- *
ZEBRA danio , *GENE expression in fishes , *PROPERDIN factor B , *STRUCTURE-activity relationships , *FUNCTIONAL analysis , *FISH larvae , *IMMUNE response , *FISH immunology - Abstract
Abstract: Properdin, an upregulator of the alternative complement pathway, has been thoroughly studied in the mammalian species, but its research in the lower vertebrates such as fish is rather limited. Additionally, information regarding the structure–activity relationship of properdin remains rather fragmentary. In this report, we showed that zebrafish properdin gene zfp was abundantly expressed in the liver of adult fish, while it was primarily expressed in the brain, neural plate, developing lens, and neutrophil in the early embryos/larvae. Recombinant TSR modules of zfP were demonstrated to be able to bind to C3b, LPS, LTA and both gram-negative and positive bacteria. Moreover, TSR5 of zfP was able to enhance the phagocytosis of microbes by macrophages. These results together support the notion that properdin is a pattern recognition molecule capable of identifying non-self antigens/structures, and indicate that TSR5 plays a central role in the capacity of properdin to promote phagocytosis. It is also suggested that properdin is associated with the pattern formation and immune defense of early developing embryos/larvae. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
13. Aurin tricarboxylic acid self-protects by inhibiting aberrant complement activation at the C3 convertase and C9 binding stages
- Author
-
Lee, Moonhee, Guo, Jian-Ping, McGeer, Edith G., and McGeer, Patrick L.
- Subjects
- *
TRICARBOXYLIC acids , *COMPLEMENT activation , *DEGENERATION (Pathology) , *PROPERDIN factor B , *CARBOXYLIC acids , *RHEUMATOID arthritis - Abstract
Abstract: Aberrant complement activation is known to exacerbate the pathology in a spectrum of degenerative diseases of aging. We previously reported that aurin tricarboxylic acid (ATA) is an orally effective agent which prevents formation of the membrane attack complex of complement. It inhibits C9 attachment to tissue bound C5b678 and thus prevents bystander lysis of host cells. In this study, we investigated the effects of ATA on the alternative complement pathway. We found that ATA prevented cleavage of the tissue bound properdin-C3b-Factor B complex into the active C3 convertase enzyme properdin-C3b-Factor Bb. This inhibition was reversed by adding Factor D to the serum. Using enzyme-linked immunosorbent type assays, we established that ATA binds directly to Factor D and C9 but not to properdin or other complement proteins. We conclude that ATA, by inhibiting at two stages of the alternative pathway, might be a particularly effective therapeutic agent in conditions such as macular degeneration, paroxysmal nocturnal hemoglobinemia, and rheumatoid arthritis, in which activation of the alternative complement pathway initiates self damage. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
14. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
- Author
-
Gou, Shen-Ju, Yuan, Jun, Chen, Min, Yu, Feng, and Zhao, Ming-Hui
- Subjects
- *
NEUTROPHILS , *CYTOPLASM , *VASCULITIS , *ENZYME-linked immunosorbent assay , *PROPERDIN factor B - Abstract
Studies in animal models suggest that complement activation is crucial in the pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Here we investigate the circulating complement activation profile of 66 patients with active stage AAV compared to that of 54 patients with AAV in remission. Plasma levels of C3a, C5a, soluble C5b-9, and Bb, all determined by enzyme-linked immunosorbent assay, were significantly higher in active stage than in remission of AAV, while plasma levels of properdin were significantly lower in the former than the latter disease stage. There was no significant difference in the plasma levels of C4d between active stage and remission. The plasma level of Bb in patients with active AAV significantly correlated with the proportion of total and cellular crescents in the renal biopsy, the erythrocyte sedimentation rate, and the Birmingham Vasculitis Activity Scores. Thus, systemic activation of complement by the alternative pathway takes place in human AAV. Circulating Bb might be a useful biomarker in assessing disease activity of AAV. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. Allotyping human complement factor B in Asian Indian type 1 diabetic patients.
- Author
-
Kumar, N., Kaur, G., Tandon, N., and Mehra, N. K.
- Subjects
- *
DIABETES , *MAJOR histocompatibility complex , *IMMUNE response , *GEL electrophoresis , *HLA histocompatibility antigens - Abstract
Human complement factor B (BF) is an essential component of the alternate complement pathway and therefore important in innate immune and autoimmune responses. The BF gene is located in the central region of major histocompatibility complex (MHC) and is known to encode more than 30 protein variants that can be resolved by isoelectric focusing and gel electrophoresis. There are three BF alleles – BF*S, BF*FB and BF*FA – that differ in codon 7 at nucleotide positions 94 and 95. These alleles have CGG, TGG or CAG triplets at their codon 7, respectively, that code for Arg, Trp or Gln residues. We have developed a novel polymerase chain reaction using sequence-specific primers-based allotyping assay that can identify nucleotide substitutions in codon 7 in all the three BF alleles. The assay was validated by sequencing and amplified fragment length polymorphism. Using this SSP assay, we report the BF alleles located on the multiple human leukocyte antigen (HLA)-DR3 haplotypes that are unique in the Indian population and are associated with autoimmunity. The common type 1 diabetes (T1D)-favoring Caucasian haplotype HLA-A1-B8-DR3 (ancestral haplotype AH8.1) carries BF*S. However, in the North Indian T1D patients, the most common haplotype is HLA-A26-B8-DR3 (AH8.2) and this carried BF*FB. Because of its association with AH8.2, the BF*FB was overrepresented in the patients (51.03%) compared with healthy controls (32.7%, OR = 2.148, 95% CI = 1.34–3.44, P = 0.002). Similar studies on allotyping BF alleles in different haplotypes in various populations could have important implications in understanding mechanisms of MHC haplotypic diversifications and disease associations and designing future therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
16. Complement genomics and antibody-mediated rejection in heart recipients.
- Author
-
Carbone, Javier
- Subjects
- *
GENOMICS , *IMMUNOGLOBULINS , *HEART transplantation , *SINGLE nucleotide polymorphisms , *PROPERDIN factor B - Abstract
In this issue of the Journal of Heart and Lung Transplantation , Marrón-Liñares et al report the results of an interesting study in which they evaluated 51 genes associated with the complement pathway in a small number of heart recipients to explore their relationship with antibody-mediated rejection (AMR). Next-generation sequencing was used in 46 heart transplant recipients (23 with AMR and 23 without AMR). The authors identified a significant association of 2 single-nucleotide polymorphisms with the absence or presence of AMR, respectively, p.Gly54Asp-MBL2 in the mannose-binding lectin (MBL) 2 gene and p.Asn428(p=)-CFP in the alternative complement factor properdin (CFP) gene. This article is a new contribution to the heart transplant literature. It suggests that complement single-nucleotide polymorphisms may influence circulating levels of selected proteins of both the lectin pathway and alternative complement pathways, thus potentially determining which patients will develop AMR. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Deficiency of C4 from brain death mice protects against renal injury.
- Author
-
Poppelaars, F., Jager, N.M., van Werkhoven, M.B., Damman, J., Hillebrand, J.L., Daha, M.R., Leuvenink, H.G.D., and Seelen, M.A.
- Subjects
- *
BRAIN death , *COMPLEMENT activation , *KIDNEY transplantation , *HEMODYNAMICS , *PROPERDIN factor B , *THERAPEUTICS - Published
- 2017
- Full Text
- View/download PDF
18. Genetic polymorphism of properdin factor B (BF) in domestic rabbit.
- Author
-
Branco, M., Lopes, G., and Ferrand, N.
- Subjects
- *
GENETIC polymorphisms , *ISOELECTRIC focusing , *ALLELES , *RABBITS , *GENETICS - Abstract
Genetic polymorphism of plasma properdin factor B (BF) was detected in domestic rabbit, Oryctolagus cuniculus , by means of isoelectric focusing and immunoblotting. The analysis of 298 individuals, corresponding to one French and two Portuguese populations, revealed the existence of six alleles, of which BF*A, B and C were common alleles, and D, F and G were rare ones. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
19. Crystallization and X‐ray analysis of monodisperse human properdin.
- Author
-
Pedersen, Dennis Vestergaard, Revel, Margot, Gadeberg, Trine Amalie Fogh, and Andersen, Gregers Rom
- Subjects
- *
PROPERDIN factor B , *CRYSTALLIZATION , *PROPROTEIN convertases - Abstract
The 54 kDa protein properdin, also known as factor P (FP), plays a major role in the complement system through the stabilization of the alternative pathway convertases. FP circulates in the blood as cyclic dimers, trimers and tetramers, and this heterogeneity challenges detailed structural insight into the mechanism of convertase stabilization by FP. Here, the generation of an intact FP monomer and a variant monomer with the third thrombospondin repeat liberated is described. Both FP monomers were excised from recombinant full‐length FP containing internal cleavage sites for TEV protease. These FP monomers could be crystallized, and complete data sets extending to 2.8 Å resolution for the intact FP monomer and to 3.5 Å resolution for the truncated variant were collected. The principle of specific monomer excision and domain removal by the insertion of a protease cleavage site may be broadly applicable to structural studies of oligomeric, flexible and modular proteins. A heterogeneous distribution of oligomers complicated the structure determination of the complement regulator properdin. Using TEV protease excision from recombinant oligomers, two types of properdin monomers could be crystallized. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Complement factor H-related (CFHR) proteins 2 and 5 as well as iC3b and properdin are deposited in different glomerular diseases.
- Author
-
Person, Fermin, Niebuhr, Norbert, Langbehn, Ulrike, Karaulashvili, Tamar, Rtskhiladze, Irakli, Thurman, Joshua M., Skerka, Christine, Rudnick, Ramona, Zipfel, Peter, and Wiech, Thorsten
- Subjects
- *
COMPLEMENT factor H , *KIDNEY disease treatments , *IMMUNOSTAINING , *PROPERDIN factor B , *RENAL biopsy - Published
- 2017
- Full Text
- View/download PDF
21. Structural studies of convertases in the complement system. The properdin-stabilised proconvertase, and the C5 convertase.
- Author
-
Gadeberg, Trine A.F., Pedersen, Dennis Vestergaard, and Andersen, Gregers Rom
- Subjects
- *
PROPROTEIN convertases , *PROPERDIN factor B , *COMPLEMENT (Immunology) , *FREEZE-drying , *COBRA venom factor - Published
- 2017
- Full Text
- View/download PDF
22. Infectious disease: Complementing antibacterial strategies.
- Author
-
Harrison, Charlotte
- Subjects
- *
PROPERDIN factor B , *STREPTOCOCCUS pneumoniae , *MOUSE diseases , *PREVENTION - Abstract
The article presents research showing the significance of recombinant properdin in protecting mice against Neisseria meningitides and Streptococcus pneumoniae infection.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.